Common Warts (Verruca Vulgaris)
Common warts, medically known as verruca vulgaris, are benign epidermal proliferations caused by infection with human papillomavirus (HPV), particularly types 2 and 4, though types 1, 3, 27, 29, 57, and others may also be implicated. These warts appear most frequently on the hands, fingers, and periungual skin, but can develop on any keratinized, non-mucosal surface. They are characterized by rough, hyperkeratotic papules or plaques that may be skin-colored, gray, or brown, and frequently exhibit thrombosed capillaries that appear as dark punctate dots on the surface. Common warts are among the most frequently encountered cutaneous viral infections worldwide, affecting up to 10% of the population, with higher prevalence in school-aged children and immunocompromised individuals. Although nonmalignant, they can lead to psychosocial distress, discomfort, and functional impairment, especially if located on high-friction or cosmetically sensitive areas.
Symptoms
Common warts typically present as firm, well-demarcated, hyperkeratotic papules or plaques ranging from 1 mm to over 1 cm in diameter. Lesions are often rough or verrucous in texture and may be solitary or grouped. They tend to occur on areas subject to trauma, such as the fingers, hands, knees, and elbows. The surface may have black punctate dots representing thrombosed dermal capillaries. Warts are usually asymptomatic but may cause pain or tenderness when located on pressure-bearing areas or subject to friction. Nail biting or periungual warts may cause nail plate distortion. Subungual and periungual warts can be particularly painful and difficult to treat. Occasionally, bleeding may occur if the wart is traumatized. Some patients report pruritus. In immunocompetent hosts, the lesions often remain static or spontaneously regress over time.
Risk Factors
Predisposing factors for the development of common warts include direct contact with HPV through broken skin, whether by minor trauma, shaving, nail-biting, or contact with contaminated surfaces. Environments such as public showers, locker rooms, swimming pools, and communal gym equipment increase the risk due to the potential for virus-laden fomites. Children and adolescents are disproportionately affected due to more frequent exposure and less developed immune defenses. Occupations involving frequent hand immersion in water, exposure to meat or fish (e.g., butchers and fishmongers), or regular use of occlusive gloves are associated with higher rates of hand warts. Immunosuppressed individuals, such as those with HIV/AIDS, solid organ transplants, or on systemic immunosuppressive therapy, are particularly susceptible, often developing extensive, recalcitrant, or atypical warts. Atopic dermatitis may also increase susceptibility due to impaired skin barrier function and increased local inflammation.
Diagnosis
The diagnosis of verruca vulgaris is primarily clinical and relies on the characteristic morphology and distribution of the lesions. The diagnostic criteria include the presence of a verrucous or papillomatous surface, interruption of skin lines, and black dots from thrombosed capillaries. Dermoscopy enhances diagnostic accuracy by revealing specific features such as finger-like projections and dotted or looped vessels. Biopsy is not routinely indicated but may be performed in atypical presentations, treatment-refractory lesions, or when malignancy is suspected. Histopathology confirms the diagnosis with findings of papillomatosis, hyperkeratosis, and koilocytosis. HPV typing is not performed routinely for cutaneous warts in clinical practice, as it does not influence treatment decisions.
Treatment
Treatment for common warts is aimed at eliminating visible lesions, reducing transmission, and relieving symptoms. First-line options include topical salicylic acid, a keratolytic agent that breaks down hyperkeratotic tissue and enhances immune recognition of the virus. Salicylic acid is typically applied daily following paring of the thickened skin. Cryotherapy with liquid nitrogen is also widely used and induces wart destruction through cellular disruption and secondary inflammation; sessions are repeated every 2 to 3 weeks. Combination therapies, such as cryotherapy with salicylic acid, demonstrate increased efficacy over monotherapy. Other options include cantharidin (a vesicant agent), imiquimod (an immune response modifier that activates toll-like receptor 7), and intralesional antigen therapy (such as Candida or mumps antigen to elicit a delayed-type hypersensitivity response). Refractory lesions may require destructive modalities such as electrosurgery, curettage, CO2 or pulsed dye laser ablation, or intralesional bleomycin. Immunocompromised patients often require more aggressive or sustained therapies and may benefit from systemic immunomodulatory agents. No single therapy guarantees success, and recurrence is common. Patient preference, lesion location, size, number, and tolerability of side effects inform treatment choice.
Outlook
The natural course of common warts is self-limiting in the majority of immunocompetent individuals, with spontaneous resolution occurring in 30% within six months and up to 70% within two years. However, recalcitrant or recurrent lesions are not uncommon, particularly in patients with compromised immunity. Prognosis is excellent, and common warts are considered non-neoplastic. In rare cases, persistent verrucae may be associated with epidermodysplasia verruciformis or may undergo transformation to verrucous carcinoma or squamous cell carcinoma, primarily in immunosuppressed individuals. Even when untreated, warts pose no systemic health risk in the vast majority of patients.
Complications
Potential complications include secondary bacterial infection, bleeding, cosmetic disfigurement, pain, especially on weight-bearing surfaces, and recurrence following treatment. Scarring may occur with aggressive modalities such as curettage or laser therapy. In immunocompromised patients, lesions may be numerous, resistant to therapy, and associated with rare HPV-related malignancies.
Prevention
Preventative strategies center on minimizing HPV exposure and maintaining skin integrity. This includes wearing flip-flops or waterproof shoes in communal wet areas, refraining from sharing razors or towels, and avoiding nail-biting or picking at hangnails. Keeping skin moisturized and intact reduces microabrasions that permit viral entry. Immunocompromised individuals may require stricter measures to avoid inoculation. There is no available vaccine for the HPV types that cause cutaneous warts; current prophylactic HPV vaccines such as Gardasil and Cervarix target mucosal HPV types and offer no protection against verruca vulgaris.
Support
Patients should be educated on the benign nature of common warts and advised to avoid trauma to lesions to reduce the risk of spread. They should keep lesions covered in communal environments, avoid sharing personal items, and wash hands frequently. Adherence to prescribed treatments, proper lesion preparation (e.g., soaking and paring), and patience are critical, as resolution may take weeks to months. Individuals with frequent recurrences may benefit from further immunologic evaluation. Support groups are generally not required but reassurance and education can alleviate psychosocial distress in pediatric or adolescent patients.
Sources
The information presented above is supported by reputable medical sources and research publications. These references provide additional clinical insights and evidence-based findings for healthcare professionals and individuals seeking comprehensive understanding of this medical condition.
